Bleeding pattern, tolerance and patient satisfaction with a drospirenone-containing oral contraceptive evaluated in 3488 women in Europe, the Middle East and Canada

Abstract Background This study was conducted to assess the bleeding pattern, tolerance and patient satisfaction associated with an oral contraceptive (OC) containing 3 mg of drospirenone and 30 mcg of ethinyl estradiol under real-life conditions. Study Design A multicenter, prospective and observati...

Full description

Saved in:
Bibliographic Details
Published in:Contraception (Stoneham) 2009-06, Vol.79 (6), p.428-432
Main Authors: Endrikat, Jan S, Milchev, Nikola P, Kapamadzija, Aleksandra, Georgievska, Jadranka, Gerlinger, Christoph, Schmidt, Werner, Feroze, Sleem
Format: Article
Language:English
Subjects:
Adolescent
Adult
Androstenes - administration & dosage
Androstenes - standards
Biological and medical sciences
Birth control
Bleeding pattern
Canada - epidemiology
Cohort Studies
Contraceptives, Oral, Combined - administration & dosage
Contraceptives, Oral, Combined - standards
Drospirenone
Ethinyl Estradiol - administration & dosage
Ethinyl Estradiol - standards
Europe - epidemiology
Female
Genital system. Reproduction
Gynecology. Andrology. Obstetrics
Hormonal contraception
Humans
Medical sciences
Metrorrhagia - chemically induced
Metrorrhagia - epidemiology
Middle East - epidemiology
Obstetrics and Gynecology
Oral contraception
Patient Satisfaction
Pharmacology. Drug treatments
Prospective Studies
Tolerance
Young Adult
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Abstract Background This study was conducted to assess the bleeding pattern, tolerance and patient satisfaction associated with an oral contraceptive (OC) containing 3 mg of drospirenone and 30 mcg of ethinyl estradiol under real-life conditions. Study Design A multicenter, prospective and observational six-cycle study was conducted in 12 countries in Europe, the Middle East and Canada. The efficacy variables included an assessment of bleeding patterns, premenstrual symptoms of water retention and patient satisfaction as determined by a visual analog scale. Results A total of 3488 women was enrolled in the study. The percentage of women with intermenstrual bleeding decreased from 27.9% at baseline to 5.4% at the end of Cycle 6, while dysmenorrhea decreased from 67% to 17.7%. Also, amenorrhea decreased from 21.3% to 7.5%. The decreases in all three parameters were statistically significant (p
ISSN:0010-7824
1879-0518
DOI:10.1016/j.contraception.2008.12.007